サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413623

破傷風トキソイドワクチン市場：ワクチンタイプ、年齢、エンドユーザー別- 世界予測2024-2030年

Tetanus Toxoid Vaccine Market by Vaccine Type (Diphtheria and Tetanus (DT), Diphtheria,Tetanus, and Pertussis (DTaP), Tetanus, Diphtheria and Pertussis (Tdap)), Age (Adults, Neonatal), End User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 197 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
破傷風トキソイドワクチン市場：ワクチンタイプ、年齢、エンドユーザー別- 世界予測2024-2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

破傷風トキソイドワクチン市場規模は2023年に55億8,000万米ドルと推計され、2024年には58億6,000万米ドルに達し、CAGR 6.75%で2030年には88億3,000万米ドルに達すると予測されます。

破傷風トキソイドワクチンの世界市場

主な市場の統計
基準年[2023］ 55億8,000万米ドル
予測年[2024］ 58億6,000万米ドル
予測年 [2030] 88億3,000万米ドル
CAGR（%） 6.75%
破傷風トキソイドワクチン Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは破傷風トキソイドワクチン市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、破傷風トキソイドワクチン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-破傷風トキソイドワクチン市場の市場規模および予測は？

2-破傷風トキソイドワクチン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-破傷風トキソイドワクチン市場における技術動向と規制の枠組みは？

4-破傷風トキソイドワクチン市場における主要ベンダーの市場シェアは？

5-破傷風トキソイドワクチン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で破傷風が大幅に蔓延
      • 破傷風ワクチンが低コストで広く入手可能
    • 抑制要因
      • ワクチンの品質欠陥による製品リコールの可能性
    • 機会
      • 啓発および予防接種プログラムに対する政府の取り組み
      • 各国にわたるコールドチェーンとヘルスケアインフラの改善
    • 課題
      • ワクチンに伴う副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 破傷風トキソイドワクチン市場ワクチンの種類別

  • ジフテリアおよび破傷風（DT）
  • ジフテリア、破傷風、百日咳（DTaP）
  • 破傷風、ジフテリア、百日咳（Tdap）

第7章 破傷風トキソイドワクチン市場年齢別

  • 大人
  • 新生児

第8章 破傷風トキソイドワクチン市場：エンドユーザー別

  • クリニック
  • 病院

第9章 南北アメリカの破傷風トキソイドワクチン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の破傷風トキソイドワクチン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの破傷風トキソイドワクチン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AJ Vaccines A/S
    • Astellas Pharma Inc.
    • BB-NCIPD Ltd.
    • Bharat Biotech Ltd.
    • Bio Farma
    • Biological E. Limited
    • Dano Vaccines & Biologicals Pvt. Ltd.
    • GlaxoSmithKline PLC
    • Haffkine Bio-Pharmaceutical Corporation Ltd.
    • Incepta Vaccine Ltd.
    • MEDZEEL LIFESCIENCE
    • Merck & Co, Inc.
    • Panacea Biotec Limited
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. TETANUS TOXOID VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. TETANUS TOXOID VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. TETANUS TOXOID VACCINE MARKET DYNAMICS
  • FIGURE 7. TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2030 (%)
  • FIGURE 10. TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. TETANUS TOXOID VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. TETANUS TOXOID VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TETANUS TOXOID VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA AND TETANUS (DT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. TETANUS TOXOID VACCINE MARKET SIZE, BY DIPHTHERIA,TETANUS, AND PERTUSSIS (DTAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. TETANUS TOXOID VACCINE MARKET SIZE, BY TETANUS, DIPHTHERIA AND PERTUSSIS (TDAP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 10. TETANUS TOXOID VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. TETANUS TOXOID VACCINE MARKET SIZE, BY NEONATAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 13. TETANUS TOXOID VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. TETANUS TOXOID VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES TETANUS TOXOID VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM TETANUS TOXOID VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. TETANUS TOXOID VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 143. TETANUS TOXOID VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. TETANUS TOXOID VACCINE MARKET LICENSE & PRICING
目次
Product Code: MRR-B1685377AB47

[197 Pages Report] The Tetanus Toxoid Vaccine Market size was estimated at USD 5.58 billion in 2023 and expected to reach USD 5.86 billion in 2024, at a CAGR 6.75% to reach USD 8.83 billion by 2030.

Global Tetanus Toxoid Vaccine Market

KEY MARKET STATISTICS
Base Year [2023] USD 5.58 billion
Estimated Year [2024] USD 5.86 billion
Forecast Year [2030] USD 8.83 billion
CAGR (%) 6.75%
Tetanus Toxoid Vaccine Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Tetanus Toxoid Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Tetanus Toxoid Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Tetanus Toxoid Vaccine Market, highlighting leading vendors and their innovative profiles. These include AJ Vaccines A/S, Astellas Pharma Inc., BB-NCIPD Ltd., Bharat Biotech Ltd., Bio Farma, Biological E. Limited, Dano Vaccines & Biologicals Pvt. Ltd., GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd., Incepta Vaccine Ltd., MEDZEEL LIFESCIENCE, Merck & Co, Inc., Panacea Biotec Limited, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Tetanus Toxoid Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Vaccine Type
    • Diphtheria and Tetanus (DT)
    • Diphtheria,Tetanus, and Pertussis (DTaP)
    • Tetanus, Diphtheria and Pertussis (Tdap)
  • Age
    • Adults
    • Neonatal
  • End User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Tetanus Toxoid Vaccine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Tetanus Toxoid Vaccine Market?

3. What are the technology trends and regulatory frameworks in the Tetanus Toxoid Vaccine Market?

4. What is the market share of the leading vendors in the Tetanus Toxoid Vaccine Market?

5. Which modes and strategic moves are suitable for entering the Tetanus Toxoid Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Tetanus Toxoid Vaccine Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant prevalence of tetanus worldwide
      • 5.1.1.2. Low cost and wide availability of tetanus vaccine
    • 5.1.2. Restraints
      • 5.1.2.1. Potential product recall due to vaccine quality defects
    • 5.1.3. Opportunities
      • 5.1.3.1. Government initiatives for awareness and immunization programs
      • 5.1.3.2. Improving cold chain and healthcare infrastructure across countries
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Tetanus Toxoid Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Diphtheria and Tetanus (DT)
  • 6.3. Diphtheria,Tetanus, and Pertussis (DTaP)
  • 6.4. Tetanus, Diphtheria and Pertussis (Tdap)

7. Tetanus Toxoid Vaccine Market, by Age

  • 7.1. Introduction
  • 7.2. Adults
  • 7.3. Neonatal

8. Tetanus Toxoid Vaccine Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Tetanus Toxoid Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tetanus Toxoid Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tetanus Toxoid Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AJ Vaccines A/S
    • 13.1.2. Astellas Pharma Inc.
    • 13.1.3. BB-NCIPD Ltd.
    • 13.1.4. Bharat Biotech Ltd.
    • 13.1.5. Bio Farma
    • 13.1.6. Biological E. Limited
    • 13.1.7. Dano Vaccines & Biologicals Pvt. Ltd.
    • 13.1.8. GlaxoSmithKline PLC
    • 13.1.9. Haffkine Bio-Pharmaceutical Corporation Ltd.
    • 13.1.10. Incepta Vaccine Ltd.
    • 13.1.11. MEDZEEL LIFESCIENCE
    • 13.1.12. Merck & Co, Inc.
    • 13.1.13. Panacea Biotec Limited
    • 13.1.14. Pfizer Inc.
    • 13.1.15. Sanofi S.A.
    • 13.1.16. Takeda Pharmaceutical Company Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing